Rituximab, a type I anti-CD20 monoclonal antibody, has transformed treatment for non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) [105,106]. This evidence concerns the gene MS4A1 and non-Hodgkin lymphoma.